Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.

Scientific reports - 30 May 2024

Nagakubo Yuki, Hirotsu Yosuke, Yoshino Mona, Amemiya Kenji, Saito Ryota, Kakizaki Yumiko, Tsutsui Toshiharu, Miyashita Yoshihiro, Goto Taichiro, Omata Masao

Abstract excerpt

Companion diagnostic (CDx) tests play important roles in identifying oncogenic driver genes and tailoring effective molecularly targeted therapies for lung cancer patients. In Japan, the Oncomine Dx target test (ODxTT) and the AmoyDx pan lung cancer PCR panel (AmoyDx) are prominent CDx tests and only one of these tests is covered by the domestic insurance system. However, these CDx tests cover different target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Multiplex Polymerase Chain Reaction

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins c-ret

Source

Open in PubMed Open full text

Identifiers

PMID: 38816489
DOI: 10.1038/s41598-024-62857-8
PMCID: PMC11139982

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.PMID 38816489Read ↗

Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.Semantic proximity Read ↗

Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.Semantic proximity Read ↗

Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.Semantic proximity Read ↗

Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.Semantic proximity Read ↗

Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.Semantic proximity Read ↗

Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

The Current Achievements of Multi-Gene Panel Tests in Clinical Settings for Patients with Non-Small-Cell Lung CancerSemantic proximity Read ↗

Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscapeSemantic proximity Read ↗

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLCSemantic proximity Read ↗

Analytical performance and concordance with next-generation sequencing of a rapid multiplexed dPCR panel for the detection of actionable DNA and RNA biomarkers in non-small cell lung cancerSemantic proximity Read ↗

Comparison of Targeted Next Generation Sequencing Assays in Non-small cell lung cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.